menu
    • menu

    Company profile for Adagene Suzhou Limited

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Adagene (Suzhou China) is a clinical stage biotech company with innovative antibody discovery and engineering technologies. Utilizing its proprietary Dynamic Precision Library Platform (DPL), Adagene is developing immuno-oncology antibodies against novel epitopes that give unique product profiles that have potential to succeed where other groups have failed. Adagene is showcasing its exceptional antibody engineering capabiliti...
    Adagene (Suzhou China) is a clinical stage biotech company with innovative antibody discovery and engineering technologies. Utilizing its proprietary Dynamic Precision Library Platform (DPL), Adagene is developing immuno-oncology antibodies against novel epitopes that give unique product profiles that have potential to succeed where other groups have failed. Adagene is showcasing its exceptional antibody engineering capabilities by building. Adagene Announces Collaboration for Discovery of Novel CAR-T with the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Adagene Suzhou LimitedChina Flag
    Country
    Country
    China
    Address
    Address
    4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park
    Telephone
    Telephone
    (86) 0512-87773632
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.adagene.com:443/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/adagene
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Adagene Reveals FDA Fast Track For Muzastotug In Cancer
    Adagene Reveals FDA Fast Track For Muzastotug In Cancer

    16 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/16/3206100/0/en/Adagene-Announces-FDA-Fast-Track-Designation-for-Muzastotug-ADG126.html

    GLOBENEWSWIRE
    16 Dec 2025
    Share Share
    Third Arc Bio teams up with Adagene to create T-cell engagers
    Third Arc Bio teams up with Adagene to create T-cell engagers

    13 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/13/3187137/0/en/Adagene-Announces-Licensing-Agreement-with-Third-Arc-Bio-for-Development-of-Two-Masked-CD3-T-Cell-Engagers-Utilizing-SAFEbody-Technology.html

    GLOBENEWSWIRE
    13 Nov 2025
    Share Share
    Adagene Doses First Patient in Ph2 Muzastotug Combo Study
    Adagene Doses First Patient in Ph2 Muzastotug Combo Study

    31 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/31/3178218/0/en/Adagene-Announces-First-Patient-Dosed-in-Randomized-Dose-Optimization-Cohort-of-the-Phase-2-Study-of-Muzastotug-ADG126-in-Combination-with-KEYTRUDA-pembrolizumab-in-Microsatellite-.html

    GLOBENEWSWIRE
    31 Oct 2025
    Share Share
    Adagene Expands SAFEbody Collab, License With Exelixis For 3 ADC
    Adagene Expands SAFEbody Collab, License With Exelixis For 3 ADC

    16 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/16/3150716/0/en/Adagene-Expands-SAFEbody-Collaboration-and-License-Agreement-with-Exelixis-to-Develop-Third-Novel-Masked-Antibody-Drug-Conjugate.html

    GLOBENEWSWIRE
    16 Sep 2025
    Share Share
    Adagene's ADG126 Highlighted in Two Presentations at 2025 CSCO
    Adagene's ADG126 Highlighted in Two Presentations at 2025 CSCO

    05 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/05/3145312/0/en/Adagene-s-ADG126-to-be-Highlighted-in-Two-Presentations-at-the-2025-Chinese-Society-of-Clinical-Oncology-CSCO-Meeting-in-Jinan-China.html

    GLOBENEWSWIRE
    05 Sep 2025
    Share Share
    Adagene to Participate in Two Investor Conferences in September
    Adagene to Participate in Two Investor Conferences in September

    26 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/26/3139243/0/en/Adagene-to-Participate-in-Two-Investor-Conferences-in-September.html

    GLOBENEWSWIRE
    26 Aug 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search